[Wells' cellulitis and bacterial necrotizing cellulitis induced by anakinra].
BACKGROUND
Anakinra is a recombinant form of the naturally occurring human interleukin-1 receptor antagonist. It is used in the treatment of rheumatoid arthritis. The most frequent side effects are injection site reactions, which seem to have a toxic mechanism.


METHODS
We report two unusual cases of injection site reactions with anakinra: a woman presented Wells' cellulitis of the thigh and a man developed serious bacterial cellulitis distinguished by deep necrosis at the site of the latest anakinra subcutaneous injection.


CONCLUSIONS
The cases are examples of serious side effects that can occur during treatment with anakinra and underline the need for careful use of this new biological agent.
Livory
M
M
Service de dermatologie, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France.
Wechsler
J
J
Revuz
J
J
Bagot
M
M
Chevalier
X
X
Poszepczynska-Guigné
E
E
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001706:Biopsy; D002481:Cellulitis / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D004802:Eosinophilia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010400:Penicillin G / Q000008:administration & dosage / Q000627:therapeutic use; D012867:Skin / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome; D014945:Wound Healing
D000305:Adrenal Cortex Hormones; D018501:Antirheumatic Agents; D053590:Interleukin 1 Receptor Antagonist Protein; D010400:Penicillin G